Free Trial
NASDAQ:NMTR

9 Meters Biopharma (NMTR) Stock Price, News & Analysis

9 Meters Biopharma logo

About 9 Meters Biopharma Stock (NASDAQ:NMTR)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
218 shs
Average Volume
315,915 shs
Market Capitalization
$1.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Receive NMTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter.

NMTR Stock News Headlines

2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
9 Meters Biopharma, Inc. (NMTRQ)
9 Meters Biopharma Inc (NMTRQ)
9 Meters Biopharma (OTC: NMTR.Q)
See More Headlines

NMTR Stock Analysis - Frequently Asked Questions

9 Meters Biopharma, Inc. (NASDAQ:NMTR) posted its earnings results on Monday, November, 15th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.26.

Shares of 9 Meters Biopharma reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/15/2021
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NMTR
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
$-43,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.19 per share

Miscellaneous

Free Float
13,992,000
Market Cap
$1.04 million
Optionable
No Data
Beta
1.36
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:NMTR) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners